Literature DB >> 26914091

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.

Sevan Dirmesropian1, James G Wood1, C Raina MacIntyre1, Philippe Beutels1,2, Anthony T Newall3.   

Abstract

High-income countries are undergoing demographic transitions towards populations with substantial larger proportions of older adults. Due to the increased susceptibility of older adults to infectious diseases and their consequences, vaccination programmes are an important health intervention to help maintain healthy ageing. While much of the existing literature suggests that current vaccination programmes targeted at older adults and the elderly are likely to be cost effective in high-income countries, we argue that it is important to more fully consider some important issues and challenges. Since the majority of vaccines have been developed for children, economic evaluations of vaccination programmes have consequentially tended to focus on this age group and on how to incorporate herd-immunity effects. While programmes targeted at older adults and the elderly may also induce some herd effects, there are other important challenges to consider in these economic evaluations. For example, age and time effects in relation to vaccine efficacy and duration of immunity, as well as heterogeneity between targeted individuals in terms of risk of infection, severity of disease and response to vaccination. For some pathogens, there is also the potential for interactions with childhood programmes in the form of herd-immunity effects.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914091     DOI: 10.1007/s40273-016-0393-0

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  67 in total

1.  Immunosenescence: impact in the young as well as the old?

Authors:  G Pawelec
Journal:  Mech Ageing Dev       Date:  1999-04-01       Impact factor: 5.432

2.  Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure.

Authors:  Graeme Hawthorne; Richard Osborne
Journal:  Aust N Z J Public Health       Date:  2005-04       Impact factor: 2.939

3.  Winter mortality modifies the heat-mortality association the following summer.

Authors:  J Rocklöv; B Forsberg; K Meister
Journal:  Eur Respir J       Date:  2008-09-17       Impact factor: 16.671

4.  The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.

Authors:  Albert Jan van Hoek; Alessia Melegaro; Nigel Gay; Joke Bilcke; W John Edmunds
Journal:  Vaccine       Date:  2011-11-23       Impact factor: 3.641

5.  Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia.

Authors:  Iman Ridda; Raina C MacIntyre; Richard I Lindley; Peter B McIntyre; John Sullivan; Gwendolyn Gilbert; Pramesh Kovoor; Nicholas Manolios; John Fox
Journal:  Hum Vaccin       Date:  2007-05-30

Review 6.  Immunity and immunization in elderly.

Authors:  Patrice Bourée
Journal:  Pathol Biol (Paris)       Date:  2003-12

Review 7.  Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

Authors:  Isla Ogilvie; Antoine El Khoury; Yadong Cui; Erik Dasbach; John D Grabenstein; Mireille Goetghebeur
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

8.  Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Felix Weidemann; Thomas Reinhold; Anette Siedler; Gérard Krause; Ole Wichmann
Journal:  BMC Health Serv Res       Date:  2013-09-26       Impact factor: 2.655

Review 9.  A systematic review of the cost effectiveness of herpes zoster vaccination.

Authors:  Thomas D Szucs; Alena M Pfeil
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.558

Review 10.  Systematic review of incidence and complications of herpes zoster: towards a global perspective.

Authors:  Kosuke Kawai; Berhanu G Gebremeskel; Camilo J Acosta
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

View more
  4 in total

1.  What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Authors:  A T Newall
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

2.  Cost-effectiveness of adult vaccinations: A systematic review.

Authors:  Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges
Journal:  Vaccine       Date:  2018-12-04       Impact factor: 3.641

3.  The implications of globalization on COVID-19 vaccination in Europe.

Authors:  Dan Lupu; Ramona Tiganasu
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

Review 4.  Vaccination programs for older adults in an era of demographic change.

Authors:  T Mark Doherty; Mark P Connolly; Giuseppe Del Giudice; Johan Flamaing; Jorg J Goronzy; Beatrix Grubeck-Loebenstein; Paul-Henri Lambert; Stefania Maggi; Janet E McElhaney; Hideaki Nagai; William Schaffner; Ruprecht Schmidt-Ott; Edward Walsh; Alberta Di Pasquale
Journal:  Eur Geriatr Med       Date:  2018-03-19       Impact factor: 1.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.